Vion Submits Laromustine For Use In Niche Population
This article was originally published in The Pink Sheet Daily
Executive Summary
Vion takes the quickest path to market for laromustine, now Onrigin, by submitting an NDA for use in elderly patients with poor prognosis.
You may also be interested in...
FDA Hold On Cloretazine Phase III Trial Is Lifted, Putting Vion On Track For 2008 NDA
Company concedes it could run out of cash in 2009 if cancer drug is not commercialized.
Vion Suspends Cloretazine Phase III Enrollment In Leukemia Patients
Suspension is a “hiccup” but development of the alkylating agent for adult myelogenous leukemia will move forward, Vion CEO Kessman states.
Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.